Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Pulmonology · Nonspecific Interstitial Pneumonia

Treatment Options and Shared Decisions

At a Glance

NSIP treatment depends on its cause, severity, and whether inflammation or scarring dominates. Doctors may use prednisone and steroid-sparing medicines for inflammation, while nintedanib may slow lung-function loss when scar-forming NSIP meets progressive pulmonary fibrosis criteria.

When you are diagnosed with a rare lung condition, it is completely normal to feel anxious about the road ahead. Treating Non-Specific Interstitial Pneumonia (NSIP) is a marathon, not a sprint. Because NSIP often involves an overactive immune system attacking the lungs, the primary goal of treatment is to “quiet” the inflammation and prevent or slow the formation of permanent scar tissue [1][2]. Your care team will tailor your treatment based on the underlying cause (such as an autoimmune disease, drug toxicity, or hypersensitivity pneumonitis), the severity of the disease, and whether it is cellular (driven by inflammation) or fibrotic (driven by scarring) [3].

Treatment Options and Shared Decisions

There is no single fixed schedule for NSIP treatment. If an offending drug or environmental antigen is identified, removing the trigger is central. For active inflammatory or progressive disease, corticosteroids and steroid-sparing immunosuppressants are options.

Corticosteroids (Prednisone)

Prednisone is an option often used to quickly reduce lung inflammation, particularly in cellular or acute presentations [4].

  • The Strategy: You may start on a higher dose to control inflammation. Once your breathing and lung function tests stabilize, your doctor will slowly taper (gradually reduce) the dose to the lowest amount that keeps you stable [5].
  • The Goal: Long-term use of high-dose steroids has significant side effects, so the aim is often to transition you to a “steroid-sparing” medication if prolonged treatment is needed [6].

Steroid-Sparing Medications

To keep the disease in check without the long-term risks of prednisone, doctors may use immunosuppressants [7]:

  • Mycophenolate Mofetil (MMF): A common choice for NSIP, especially if it is related to an autoimmune disease, as it can help maintain lung function [8][9][10].
  • Azathioprine: An alternative to MMF. While effective for some, it requires careful blood monitoring and genetic testing [11][8].

Escalation for Severe or Refractory Disease

If the disease is very severe or refractory, particularly in the context of connective-tissue-disease (CTD) or autoimmune ILD, an ILD/rheumatology specialist may recommend more intensive treatments [12].

  • Rituximab: This is an infusion medication that targets specific immune cells (B-cells) [13]. It is used selectively in severe autoimmune ILD, and evidence supports it as an escalation strategy, though it carries risks of serious viral infections and infusion reactions [9].
  • Cyclophosphamide: Typically reserved for the most severe cases or refractory disease, this is a powerful medication [14]. Because of its strength and toxicity, it is usually only used under strict specialist supervision [15].

The Role of Anti-Fibrotics (Nintedanib)

In some cases of NSIP—specifically the fibrotic subtype—the lungs may continue to scar even when the immune system is under control [16]. This is called Progressive Pulmonary Fibrosis (PPF) [17].

Progressive pulmonary fibrosis is assessed over a defined period (usually a year) and generally requires a clinically meaningful combination of worsening symptoms, radiologic progression, and physiologic decline [18]. If you meet these criteria, your doctor may add nintedanib. Nintedanib does not reverse established scar, but it can slow the loss of lung function in selected progressive fibrosing ILDs [19]. Its use with mycophenolate is individualized and depends on local guidelines [12][6].

Safety and Infection Prevention

Because these treatments “turn down” your immune system, you must be proactive about preventing infections [20].

  1. PJP Prophylaxis: Depending on your steroid dose, duration, and combination of immunosuppressants, your clinician will determine if you need an antibiotic (like trimethoprim-sulfamethoxazole) to prevent Pneumocystis jirovecii pneumonia (PJP) [21][7][22]. This is highly individualized.
  2. Vaccinations: It is critical to be up-to-date on your pneumococcal, COVID-19, and influenza vaccines. Discuss vaccine timing and live-vaccine restrictions with your team [20].
  3. Do not change doses: Never stop or change your medication doses without direct instruction from your prescribing team.

Drug-Specific Side Effect Monitoring

Medication Class Common Side Effects & Specific Risks Standard Monitoring
Corticosteroids Weight gain, mood changes, adrenal suppression, fracture risk, eye disease (cataracts), high blood sugar [4] Blood pressure, glucose, bone density scans, eye exams
Mycophenolate (MMF) Nausea, diarrhea, increased infection risk, severe pregnancy risks [8] Complete Blood Count (CBC), Liver Function Tests (LFTs), kidney function, strict contraception
Azathioprine Nausea, liver toxicity, low white blood cells CBC, LFTs, TPMT/NUDT15 genetic screening prior to use
Cyclophosphamide Bone marrow suppression, fertility impact, bladder toxicity Urinalysis, CBC, strict specialist monitoring
Rituximab Infusion reactions, severe viral infections Hepatitis B screening prior to use, immunoglobulin levels
Anti-fibrotics (Nintedanib) Diarrhea (very common), nausea, bleeding risks, cardiovascular considerations [23] LFTs, weight monitoring

Common questions in this guide

How is treatment for NSIP chosen?
Treatment is tailored to the underlying cause, disease severity, and whether the lung pattern is mainly inflammatory or scar-forming. Removing an offending drug or environmental trigger is important when one is identified. Active or progressive disease may require prednisone, a steroid-sparing medicine, or other specialist treatment.
How is prednisone used and tapered for NSIP?
Prednisone may be started at a higher dose to reduce active lung inflammation. When breathing and lung function stabilize, the prescribing clinician usually lowers the dose gradually to the lowest effective amount, often while transitioning to a steroid-sparing medicine if longer treatment is needed. Do not stop or change prednisone without medical guidance.
Which medicines can reduce the need for long-term steroids in NSIP?
Mycophenolate mofetil is commonly used, especially when NSIP is associated with autoimmune disease, and azathioprine may be an alternative. These medicines can still suppress the immune system and require blood or organ-function monitoring. Your specialist will choose based on your health, other medicines, and treatment response.
When might nintedanib be used for NSIP?
Nintedanib may be considered when scar-forming NSIP continues to worsen and meets criteria for progressive pulmonary fibrosis. These criteria generally combine worsening symptoms, changes on imaging, and declining lung function over a defined period. Nintedanib does not remove existing scar tissue but may slow further loss of lung function in selected patients.
How can I reduce infection risk during NSIP treatment?
Prednisone and other immune-suppressing medicines can increase infection risk. Depending on the doses and combinations used, your clinician may recommend an antibiotic to prevent Pneumocystis jirovecii pneumonia and may update pneumococcal, influenza, and COVID-19 vaccinations. Ask your care team about vaccine timing and what to do if you develop a fever, rash, or other signs of infection.
What monitoring is needed while taking NSIP medicines?
Monitoring depends on the medicine and may include complete blood counts, liver and kidney tests, blood pressure, blood sugar, bone density, eye exams, or urinalysis. Azathioprine may require TPMT or NUDT15 testing, rituximab requires hepatitis B screening, and nintedanib commonly requires liver-test monitoring. Your care team should explain how often each test is needed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the primary goal of my current treatment—controlling inflammation, slowing fibrosis, or treating an underlying autoimmune condition?
  2. 2.What is our plan for tapering my prednisone dose to minimize long-term side effects?
  3. 3.Do I meet the criteria for 'progressive pulmonary fibrosis' that would make me a candidate for an anti-fibrotic like nintedanib?
  4. 4.Based on my medication dose and risk factors, should I be on a prophylactic antibiotic to prevent PJP infection?
  5. 5.What specific blood tests (e.g., CBC, liver enzymes) do I need, and how often will we monitor them for drug side effects?
  6. 6.Are my vaccinations—especially for pneumonia, flu, and COVID-19—up to date before starting intensive immunosuppression?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Nonspecific Interstitial Pneumonia.

    Teoh AKY, Corte TJ

    Seminars in respiratory and critical care medicine 2020; (41(2)):184-201 doi:10.1055/s-0040-1708499.

    PMID: 32279290
  2. 2

    Nonspecific Interstitial Pneumonia: What Is the Optimal Approach to Management?

    Tomassetti S, Ryu JH, Piciucchi S, et al.

    Seminars in respiratory and critical care medicine 2016; (37(3)):378-94 doi:10.1055/s-0036-1583176.

    PMID: 27231862
  3. 3

    Idiopathic non-specific interstitial pneumonia.

    Belloli EA, Beckford R, Hadley R, Flaherty KR

    Respirology (Carlton, Vic.) 2016; (21(2)):259-68 doi:10.1111/resp.12674.

    PMID: 26564810
  4. 4

    Korean Guidelines for Diagnosis and Management of Idiopathic Nonspecific Interstitial Pneumonia.

    Jo YS, Lee HK, Park SH, et al.

    Tuberculosis and respiratory diseases 2025; (88(2)):237-246 doi:10.4046/trd.2024.0168.

    PMID: 39761948
  5. 5

    One-year clinical experience on the use of Nintedanib in systemic sclerosis.

    Magnani L, Spinella A, Testoni S, et al.

    Respirology case reports 2023; (11(6)):e01120 doi:10.1002/rcr2.1120.

    PMID: 37229296
  6. 6

    Combination antifibrotic and immunosuppressive therapy in progressive fibrosing ILD.

    Fischer R, Abdul Rehman K

    Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2026; (43(1)):18462 doi:10.36141/svdld.2026.18462.

    PMID: 41891405
  7. 7

    Immunomodulatory treatment of interstitial lung disease.

    van den Bosch L, Luppi F, Ferrara G, Mura M

    Therapeutic advances in respiratory disease 2022; (16()):17534666221117002 doi:10.1177/17534666221117002.

    PMID: 35938712
  8. 8

    Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

    Oldham JM, Lee C, Valenzi E, et al.

    Respiratory medicine 2016; (121()):117-122 doi:10.1016/j.rmed.2016.11.007.

    PMID: 27888985
  9. 9

    Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

    Mankikian J, Caille A, Reynaud-Gaubert M, et al.

    The European respiratory journal 2023; (61(6)) doi:10.1183/13993003.02071-2022.

    PMID: 37230499
  10. 10

    Variables Associated With Response to Therapy in Patients With Interstitial Pneumonia With Autoimmune Features.

    Joerns EK, Adams TN, Newton CA, et al.

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2022; (28(2)):84-88 doi:10.1097/RHU.0000000000001808.

    PMID: 34897197
  11. 11

    Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia.

    Cho HK, Chung MP, Soo Lee K, et al.

    Therapeutic advances in respiratory disease 2022; (16()):17534666221089468 doi:10.1177/17534666221089468.

    PMID: 35400267
  12. 12

    Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline.

    Raghu G, Montesi SB, Silver RM, et al.

    American journal of respiratory and critical care medicine 2024; (209(2)):137-152 doi:10.1164/rccm.202306-1113ST.

    PMID: 37772985
  13. 13

    Rituximab in connective tissue disease-associated interstitial lung disease.

    Duarte AC, Cordeiro A, Fernandes BM, et al.

    Clinical rheumatology 2019; (38(7)):2001-2009 doi:10.1007/s10067-019-04557-7.

    PMID: 31016581
  14. 14

    Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

    Maher TM, Tudor VA, Saunders P, et al.

    The Lancet. Respiratory medicine 2023; (11(1)):45-54 doi:10.1016/S2213-2600(22)00359-9.

    PMID: 36375479
  15. 15

    Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial.

    Saunders P, Tsipouri V, Keir GJ, et al.

    Trials 2017; (18(1)):275 doi:10.1186/s13063-017-2016-2.

    PMID: 28619061
  16. 16

    Computed tomography findings of current nonspecific interstitial pneumonia based on the 2013 updated classification of idiopathic interstitial pneumonias: What is a characteristic of previously diagnosed nonspecific interstitial pneumonia excluded from the updated classification.

    Tominaga J, Iwasawa T, Murota M, et al.

    Japanese journal of radiology 2021; (39(1)):47-55 doi:10.1007/s11604-020-01036-x.

    PMID: 32875470
  17. 17

    Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.

    Pugashetti JV, Adegunsoye A, Wu Z, et al.

    American journal of respiratory and critical care medicine 2023; (207(1)):69-76 doi:10.1164/rccm.202201-0124OC.

    PMID: 35943866
  18. 18

    Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.

    Wells AU, Flaherty KR, Brown KK, et al.

    The Lancet. Respiratory medicine 2020; (8(5)):453-460 doi:10.1016/S2213-2600(20)30036-9.

    PMID: 32145830
  19. 19

    Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome.

    van den Hoogen LL, van Laar JM

    Best practice & research. Clinical rheumatology 2020; (34(1)):101485 doi:10.1016/j.berh.2020.101485.

    PMID: 32067925
  20. 20

    Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.

    Mecoli CA, Christopher-Stine L

    Current rheumatology reports 2018; (20(5)):27 doi:10.1007/s11926-018-0731-7.

    PMID: 29637383
  21. 21

    Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.

    Hsu HC, Chang YS, Hou TY, et al.

    Clinical rheumatology 2021; (40(9)):3755-3763 doi:10.1007/s10067-021-05660-4.

    PMID: 33646447
  22. 22

    Clinical features, treatment and risk factors for interstitial pneumonia in B-cell non-Hodgkin lymphoma patients.

    Li C, Lu F, Lei T, et al.

    Translational cancer research 2020; (9(9)):5139-5146 doi:10.21037/tcr-20-988.

    PMID: 35117880
  23. 23

    Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

    Flaherty KR, Wells AU, Cottin V, et al.

    The New England journal of medicine 2019; (381(18)):1718-1727 doi:10.1056/NEJMoa1908681.

    PMID: 31566307

This page explains NSIP treatment choices and medication safety for informational purposes only and does not constitute medical advice. Your pulmonologist and other specialists should guide medication changes, monitoring, vaccinations, and infection prevention for your situation.

Get notified when new evidence is published on Non-specific interstitial pneumonia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.